Search
Enter keywords, a title or a report id number below.
Your Search for 'Generic Drugs: Global collaboration opportunities' returned 107 results - Page 1 of 6
Sort by
Sorted by
Rank
Top-Bottom
-
Global Generic Injectables Market 2009-15
Avalon Global Research, Oct 2010 , Pages: 20Global Generic Injectables Market 2009-15 As majority of the blockbuster drugs are set to go off patent in the next few years, $140 bn injectables market is set to assume prominence as the fastest ... -
Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies
Spectra Intelligence, Nov 2011 , Pages: 66presented widely on various aspects of respiratory disease, on the analysis of diverse therapeutic segments, generic opportunities and on Orphan Drugs. Dr. Norman has extensive experience of the ... -
Outlook of China Drug Formulation Market
JZMed Inc, May 2011 , Pages: 230global competitive landscape. The report is a must-read book to all global pharmaceutical and biotechnology companies seeking marketing opportunities in China and collaboration with Chinese drug companies ... -
Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
Transparency Market Research, Jan 2013 , Pages: 112covers the performance of the various drugs class segment used in liver disease therapeutics in terms of their revenue. The global market for liver diseases therapeutics is classified into seven drug class ... -
The World Generic Market Report 2012
Espicom Business Intelligence Ltd, Mar 2012 , Pages: 552The World Generic Market Report 2012 A complete global analysis of the prospects for markets and companies in this dynamic industry sector Features and benefits of this thoroughly-researched and ... -
Protein Drugs - Global Strategic Business Report
Global Industry Analysts, Inc, Aug 2010 , Pages: 524Protein Drugs - Global Strategic Business Report This report analyzes the Global market for Protein Drugs in US$ Million by the following Drug Classes - Antibodies, Blood Products, Cytokines, Peptide ... -
Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech
MP Advisors, Jan 2013 , Pages: 110companies (Rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is ... -
Prescription Drugs - Global Strategic Business Report
Global Industry Analysts, Inc, Jul 2009 , Pages: 1810Prescription Drugs - Global Strategic Business Report This report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following therapeutic class – Oncologics/ Cancer Drugs ... -
Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?
FirstWord Publishing, Nov 2011 , Pages: 47drugs in Europe What are biosimilars? - Generics and biosimilars – similarities and differences - Biosimilars available so far in Europe The market opportunities for biosimilars in Europe - The ... -
Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward
GBI Research, Jun 2012 , Pages: 54Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward GBI Research, the leading business intelligence provider, has released its ... -
Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report
Global Industry Analysts, Inc, Oct 2010 , Pages: 565Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ million by the following Therapeutic Categories ... -
Alzheimers and Parkinsons Disease - Global Strategic Business Report
Global Industry Analysts, Inc, May 2008 , Pages: 530Overview II-2 Key Brands in NDD Market II-2 Table 1: Leading Drugs in the Global Neurodegenerative Disease Market (2004 ... -
The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways
GBI Research, Dec 2009 , Pages: 97first biosimilar was only launched in October 2009. However, the market is expected to gather pace due to the emergence of generic-friendly policies in Japan. The global market for biosimilars was valued ... -
Osteoporosis Therapeutics - Global Business Strategic Report
Global Industry Analysts, Inc, May 2012 , Pages: 455, which opens up a wide range of opportunities for the pharmaceutical companies. The osteoporosis therapeutic market comprises drugs that either enhance bone formation or minimize bone resorption. Various ... -
The Top 10 CMOs in India: Market Dynamics, Competitive Positioning and Trends
Scripp Business Insights, Oct 2010 , Pages: 107Indian CMOs/CRAMS companies. - Develop insights on the Indian CMO market, including market size forecast, and future outlook of global CRAMS industry and opportunities in India. - Discover contract ... -
Pricing and Reimbursement Risk and Opportunities in Pharmaceutical Deal Making
PharmaDeals, Jul 2007 , Pages: 88controlling public spending on this new and very politically sensitive initiative. Chapter 4 looks at the impact biotech drugs have had on the market to date and the future pricing opportunities and ... -
Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players
GBI Research, Apr 2013 , Pages: 97represents a great deal of opportunity for generic manufacturers. Historically, the Japanese pharmaceutical market has favored domestic companies. However, since the 1990s, deregulation has promoted ... -
Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2013
Global Markets Direct, Apr 2013 , Pages: 493reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Takeda ... -
Dealmaking and Business Strategies in the Age of Personalized Medicine
Decision Resources, Inc, Mar 2009 , Pages: 31, resurrecting failed drugs, adaptive trial design, electronic data capture, global phenotype mapping, post-traumatic stress disorder, angiotensin-converting enzyme (ACE)-inhibitor induced angioedema. - Policy ... -
Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022
GlobalData, Mar 2013 , Pages: 63Unmet Needs Gap Analysis 6.4 Opportunities 6.4.1 Treatments for Progressive MS 6.4.2 Targeting Patients with Clinically Isolated Syndrome 7 Pipeline Assessment 7.1 Overview 7.2 Promising Drugs in ...
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
